Inflammatory bowel disease is an increasingly crowded market with an influx of novel therapies recently launched or nearing approvals. The good news for up-and-coming treatments is that established products leave a lot of room for improvement. The bad news is that novel drugs for ulcerative colitis and Crohn’s disease will compete with entrenched therapeutics, such as AbbVie Inc.’s TNF inhibitor Humira (adalimumab) and Johnson & Johnson’s interleukin-12 (IL-12)/IL-23 inhibitor Stelara (ustekinumab), for which biosimilars will be available in the next one to two years.
While anti-TNF biologics and other advanced therapies are the standard of care after conventional front-line therapeutics for ulcerative colitis (UC)...
